GLP-1 receptor agonists are best known for their role in diabetes and weight management — but emerging research suggests they may also help reduce substance cravings and addictive behaviors. Our guest presenter is Steven Klein MD,PhD, who has been profiled in The New York Times and Financial times, and STAT News for his cutting-edge treatment of addiction with GLP-1s. He will provide an accessible, evidence-based overview for all healthcare providers, even those who do not specialize in addiction medicine.
What you’ll learn in this webinar:
- The neurobiological links between GLP-1 signaling, reward pathways, and addiction.
- Current evidence on GLP-1 use in alcohol, nicotine, and other substance use disorders.
- Potential applications beyond traditional substance addictions, including behavioral addictions.
- Practical considerations: safety, prescribing pearls, and how to integrate this knowledge into everyday practice.
- How GLP-1s might complement, not replace, existing therapies.
Who should attend: Physicians, nurse practitioners, physician assistants and other healthcare professionals interested in broadening their understanding of GLP-1s and their potential role in addressing addictive behaviors.
Join us to explore this exciting frontier in patient care and leave with insights you can apply immediately to your existing patient base, even if you don’t consider yourself an addiction specialist.
